Levodopa (Carbidopa/Levodopa)
Treatment for Parkinson S Disease
Typical Dosage: Carbidopa/Levodopa 25/100 mg, 3-5 times daily
Effectiveness
92%
Safety Score
65%
Clinical Trials
171
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Carbidopa/Levodopa 25/100 mg, 3-5 times daily
Time to Effect
30-90 minutes
Treatment Duration
Lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$450
Monitoring:$900
Side Effect Mgmt:$750
Total Annual:$2,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$2,470.59
Levodopa (Carbidopa/Levodopa) Outcomes
for Parkinson S Disease
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+85%
Common Side Effects
Nausea
+25%
Dyskinesia (long-term)
+40%
Hallucinations
+15%
Orthostatic Hypotension
+15%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Levodopa (Carbidopa/Levodopa) in Parkinson S Disease
Stalevo in Early Wearing-Off Patients
NCT00125567COMPLETEDPHASE4
223 participants
INTERVENTIONAL
Aalborg, Denmark +18 more
Started: Aug 1, 2005
Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off
NCT00391898COMPLETEDPHASE4
95 participants
INTERVENTIONAL
A Coruña, Spain +25 more
Started: Oct 1, 2006
Measuring Parkinson's Disease Progression
NCT03205956COMPLETEDPHASE1
31 participants
INTERVENTIONAL
St Louis, United States
Started: Oct 19, 2017
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
NCT01026428COMPLETEDPHASE1, PHASE2
24 participants
INTERVENTIONAL
Casino, Italy +1 more
Started: Sep 1, 2009
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
NCT00099268COMPLETEDPHASE3
747 participants
INTERVENTIONAL
Birmingham, United States +72 more
Started: Sep 1, 2004
Pharmacokinetic Study in Healthy Volunteers
NCT02554734COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Turku, Finland
Started: Aug 1, 2015
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease
NCT00558337COMPLETEDPHASE2
78 participants
INTERVENTIONAL
Buenos Aires, Argentina +8 more
Started: Nov 1, 2007
Levodopa Concentration Profile With Stalevo 75/125 mg
NCT01070628COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Espoo, Finland
Started: Dec 1, 2009
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
NCT02486432COMPLETEDPHASE1
6 participants
INTERVENTIONAL
Started: Apr 1, 2015
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
NCT01470859COMPLETEDNA
30 participants
INTERVENTIONAL
Shanghai, China
Started: Dec 1, 2011
PharmacoMRI of Parkinson Disease
NCT01528592COMPLETEDNA
18 participants
INTERVENTIONAL
Chicago, United States
Started: Jun 1, 2011
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)
NCT02764125COMPLETEDPHASE2
84 participants
INTERVENTIONAL
Turku, Finland +3 more
Started: Apr 8, 2016
Pharmacokinetic Study in Healthy Males
NCT02312232COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Turku, Finland
Started: Nov 1, 2014
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
NCT01130493COMPLETEDPHASE3
110 participants
INTERVENTIONAL
Fresno, United States +23 more
Started: May 1, 2010
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
NCT01617135COMPLETEDPHASE2
25 participants
INTERVENTIONAL
Petah Tikva, Israel +6 more
Started: May 1, 2012
A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612
NCT01883505COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Jerusalem, Israel +2 more
Started: Jan 6, 2014
Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
NCT00143026COMPLETEDPHASE4
184 participants
INTERVENTIONAL
Adelaide, Australia +17 more
Started: Jul 1, 2005
Showing 20 of 172 total trials